期刊文献+

康莱特联合体部伽玛刀治疗局部晚期胰腺癌28例 被引量:5

Kanglaite Injection Combined with γ-ray Stereotactic Body Radiation Therapy for 28 Cases with Locally Advanced Pancreatic Cancer
原文传递
导出
摘要 [目的]观察康莱特注射液(Kanglaite injection,KLT)联合体部伽玛刀对局部晚期胰腺癌的治疗效果。[方法]55例局部晚期胰腺癌患者随机分为两组,研究组28例:采用体部伽玛刀治疗,PTV覆盖95%以上临床靶体积(clinical target volume,CTV),等剂量曲线为50%~60%。肿瘤单次周边剂量3.0~4.5Gy,治疗9~12次,同时给予康莱特注射液200ml/d,21d为1个疗程,共2个疗程。对照组:单纯行体部伽玛刀治疗。3个月后评价疗效,通过KPS评分、体重及疼痛变化,观察生存质量改善情况。[结果]两组完全缓解率分别为28.6%(8/28)和18.5%(5/27);有效率分别为82.1%(23/28)和74.1%(20/27)。研究组Ⅲ级以上胃肠道反应发生率为3.5%(1/28),对照组为29.6%(8/27);研究组未发生Ⅲ级以上骨髓抑制(0/28),对照组为18.5%(5/27);研究组未发生Ⅲ级以上放射性肠炎(0/28),对照组为14.8%(4/27);研究组治疗前后KPS评分、体重增高及疼痛症状缓解明显高于对照组(P〈0.05)。[结论]体部伽玛刀治疗局部晚期胰腺癌安全有效,可提高局控率和有效率。康莱特配合体部伽玛刀治疗胰腺癌可以减轻治疗过程中胃肠道反应,减少Ⅲ级以上骨髓抑制和Ⅲ级以上放射性肠炎的发生,减轻疼痛症状,改善患者的生存质量。 [Purpose] To evaluate the clinical efficacy and toxicity of Kanglaite injection combined with γ-ray body stereotactic radiation in the treatment of locally advanced pancreatic cancer. [Methods] Fifty-five patients with locally advanced pancreatic cancer were randomized into two groups.The combination group received γ-ray stereotactic body radiation with isodose curve of 50%~60%,tumor encircling dose of 3.0~4.5 Gy per fraction for 9~12 fractions.Combined with Kanglaite injection 200ml/d for consecutive 21 days for two courses. Control group underwent γ-ray stereotactic body radiation alone.Toxicities and response were evaluated according to the criteria of WHO and RTOG. [Results]The CR in combination group and control group was 28.6%(8/28) and 18.5%(5/27)respectively(P 0.05).Response rate of combination group was 82.1%(23/28)and 74.1%(20/27)in control group(P 0.05).The rate of grade 3 ~4 gastrointestinal tract side reaction,grade 3 ~4 myelosuppression and grade 3 ~4 radiation enterocolitis in combination group and control group were 3.5%(1/28),0%(0/28),0%(0/28)and 29.6%(8/27),18.5%(5/27),14.8%(4/27),respectively(P 0.05).KPS and body weight score significantly increased and pain relieved in combination group after treatment(P0.05).[Conclusion] Body gamma system treatment for pancreatic carcinoma can improve local control rate and effect for inoperable patients with local advanced pancreatic carcinoma. Kanglaite injection combined with γ-ray stereotactic body radiation Therapy can relieve severe toxicity in the treatment of locally advanced pancreatic cancer and improve quality of life.
出处 《中国肿瘤》 CAS 2013年第11期931-934,共4页 China Cancer
关键词 康莱特注射液 体部伽玛刀 胰腺癌 Kanglaite injection γ-ray stereotactic body radiation therapy pancreatic cancer
  • 相关文献

参考文献9

二级参考文献55

  • 1陈光耀.临床肿瘤医师如何善用放射外科的新利器[J].中国肿瘤临床,2007,34(1):1-5. 被引量:16
  • 2仇晓军,马剑波,季斌,赵洪瑜.康莱特加同步放化疗治疗局部晚期非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):131-133. 被引量:14
  • 3Lu Y,Li CS,Dong Q.Chinese herb related molecules of cancer cell apoptosis:a minireview of progress between Kanglaite injection and related genes[J].J Exp Clin Cancer Res,2008,8:27-31.
  • 4美国癌症联合委员会(AJCC).A-JCC癌症分期手册[M].第6版.NewYork:Springer-Verlag,2002,.
  • 5Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarci- noma of the pancreas: a population- based study (United States)[J]. Cancer Causes Control, 2006, 17(4): 403-409.
  • 6Wray C J, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: re- cent controversies and current practice [J]. Gastroenterology, 2005, 128 (6): 1626-1641.
  • 7Lygidakis N J, Sgourakis G, Georgia D, et al. Regional targeting chemo im- munotherapy in patients undergoing pancreatic in an advanced stage of their disease a prospective randomized study[J]. Ann Surg, 2002, 236(6): 806-813.
  • 8John P, Neoptolemos JP, Deborah D, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemo radia- tion and/or chemotherapy in the ESPAC- 1 randomized controlled trial [J]. Ann Surg, 2001, 234(6): 758-768.
  • 9Burris HA 3rd, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomizedtrial[J]. J Clin Oneol, 1997, 15(6): 2403- 2413.
  • 10Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine com- pared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group [J].J Clin 0ncol,2007,25(15):1960-1966.

共引文献57

同被引文献103

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部